Editorial: Risk of cardiovascular events and cyclooxygenase-2 inhibitors ||FREE PAPER||

Reza Tabrizchi

Division of Basic Medical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St John’s, NL, Canada

Selective cyclooxygenase-2 (Cox-2) inhibitors have been at the centre of public attention since the revelation that the use of these drugs is associated with an increased risk of cardiovascular events (Tabrizchi 2005). Certainly pharmaco vigilance has an important place in the public domain and any new therapeutic information that leads to an increased level of physician–patients awareness has to be received with high degree of priority.